Monkeypox(Mpox),a zoonotic infection caused by the Mpox virus,has reemerged as a global public health concern,with unique implications for neonatal health.Although rare in newborns,cases of neonatal Mpox pose signific...Monkeypox(Mpox),a zoonotic infection caused by the Mpox virus,has reemerged as a global public health concern,with unique implications for neonatal health.Although rare in newborns,cases of neonatal Mpox pose significant diagnostic and therapeutic challenges due to limited clinical data and the vulnerability of this population.This narrative review explores the pathophysiology,clinical presentation,diagnostic barriers,and therapeutic strategies associated with Mpox in neonates.Vertical and perinatal transmission have been identified,with some cases presenting with vesicular rashes,fever,lymphadenopathy,and systemic involvement such as respiratory or neurological complications.Diagnosis often relies on polymerase chain reaction testing,yet resource limitations and symptom overlap with other neonatal infections can hinder accurate identification.Antiviral treatments like tecovirimat and cidofovir are considered in severe cases,but dosing in neonates remains uncertain due to a lack of robust safety data.Supportive care,including hydration,fever management,and prevention of secondary infections,is critical.Breastfeeding decisions require individualized assessment due to the unknown risk of viral transmission through breast milk.Preventive strategies emphasize early isolation,surveillance,and infection control measures in neonatal care settings.The review highlights significant research gaps in understanding neonatal Mpox,especially concerning long-term outcomes and optimal treatment protocols.A coordinated global effort is essential to improve diagnostics,develop safe therapeutic options,and establish evidence-based guidelines tailored to neonates.展开更多
文摘Monkeypox(Mpox),a zoonotic infection caused by the Mpox virus,has reemerged as a global public health concern,with unique implications for neonatal health.Although rare in newborns,cases of neonatal Mpox pose significant diagnostic and therapeutic challenges due to limited clinical data and the vulnerability of this population.This narrative review explores the pathophysiology,clinical presentation,diagnostic barriers,and therapeutic strategies associated with Mpox in neonates.Vertical and perinatal transmission have been identified,with some cases presenting with vesicular rashes,fever,lymphadenopathy,and systemic involvement such as respiratory or neurological complications.Diagnosis often relies on polymerase chain reaction testing,yet resource limitations and symptom overlap with other neonatal infections can hinder accurate identification.Antiviral treatments like tecovirimat and cidofovir are considered in severe cases,but dosing in neonates remains uncertain due to a lack of robust safety data.Supportive care,including hydration,fever management,and prevention of secondary infections,is critical.Breastfeeding decisions require individualized assessment due to the unknown risk of viral transmission through breast milk.Preventive strategies emphasize early isolation,surveillance,and infection control measures in neonatal care settings.The review highlights significant research gaps in understanding neonatal Mpox,especially concerning long-term outcomes and optimal treatment protocols.A coordinated global effort is essential to improve diagnostics,develop safe therapeutic options,and establish evidence-based guidelines tailored to neonates.
